Agios Pharmaceuticals

red blood cells

Biotech

Agios signs $165M deal for blood disorder drug that failed study

Days after its lead clinical-stage asset suffered a setback, Agios has rebounded by buying a blood disorder drug that flunked a phase 2 study.

James Waldron Jun 1, 2026 9:26am

An artists 3D rendering of cancerous blood cells among healthy red blood cells The cells fill the image and are of various

Agios’ next-gen PK drug fails ph. 2 blood cancer study

May 29, 2026 9:13am

Graphic of a couple of blood transfusion bags

Agios' next-up PK med quelled transfusion need in some patients

Nov 20, 2023 11:24am

visual of red blood cells

Agios pays $17.5M for Alnylam's siRNA blood disease program

Aug 3, 2023 8:40am

Servier Pharmaceuticals

Servier’s $1.8B bet on Agios delivers phase 3 brain tumor win

Mar 14, 2023 10:15am

ships seas storms

How 2 biotechs survived 2022’s stormy seas, per their CEOs

Jan 18, 2023 10:00am